Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
|
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [21] B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma
    Yamada, Takehiro
    Miki, Yasuhiro
    Suzuki, Miho
    Kondoh, Osamu
    Saito-Koyama, Ryoko
    Ono, Katsuhiko
    Okada, Yoshinori
    Sasano, Hironobu
    CANCER MEDICINE, 2022, 11 (02): : 479 - 491
  • [22] Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
    Cheng, Ying
    Li, Hui
    Zhang, Liang
    Liu, Jing-Jing
    Yang, Chang-Liang
    Zhang, Shuang
    CHINESE MEDICAL JOURNAL, 2021, 134 (15) : 1780 - 1788
  • [23] Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer
    Cheng Ying
    Li Hui
    Zhang Liang
    Liu Jing-Jing
    Yang Chang-Liang
    Zhang Shuang
    中华医学杂志英文版, 2021, 134 (15) : 1780 - 1788
  • [24] FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
    Sul, Joohee
    Blumenthal, Gideon M.
    Jiang, Xiaoping
    He, Kun
    Keegan, Patricia
    Pazdur, Richard
    ONCOLOGIST, 2016, 21 (05): : 643 - 650
  • [25] Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer
    Zaleski, M.
    Sharzehi, S.
    Voland, R.
    Varlotto, J.
    Rassaei, N.
    Liu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S949 - S949
  • [26] Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition
    Liang, Wenhua
    Guo, Minzhang
    Pan, Zhenkui
    Cai, Xiuyu
    Li, Caichen
    Zhao, Yi
    Liang, Hengrui
    Yang, Haiying
    Wang, Zhen
    Chen, Wenting
    Xu, Chuhong
    Yang, Xinyun
    Sun, Jianyu
    He, Ping
    Gu, Xia
    Yin, Weiqiang
    He, Jianxing
    CANCER SCIENCE, 2019, 110 (06) : 2014 - 2021
  • [27] Programmed Death-ligand 1 Expression Analysis for Non-small Cell Lung Cancer in Tissues Sampled Using Different Methods
    Urer, Halide Nur
    Gunluoglu, Mehmet Zeki
    Cansever, Levent
    Bedirhan, Mehmet Ali
    HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2020, 58 (02): : 135 - 141
  • [28] Programmed Death-Ligand 1 of Cytology Specimens as a Promising Method for Maker Evaluation in Patients of Non-Small Cell Lung Cancer
    Dong, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S923 - S923
  • [29] Petals and Thorns in Programmed Death-Ligand 1 Testing: Is All Non-Small Cell Lung Cancer Diagnostic Material Suitable?
    Bravaccini, Sara
    Bronte, Giuseppe
    CANCER CYTOPATHOLOGY, 2018, 126 (09) : 817 - 818
  • [30] The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
    Ma, Guangzhi
    Deng, Yunfu
    Jiang, Hai
    Li, Wen
    Wu, Qiang
    Zhou, Qinghua
    CLINICA CHIMICA ACTA, 2018, 482 : 101 - 107